



*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

## Revision of Precautions

### Panitumumab (genetical recombination)

August 6, 2015

#### **Non-proprietary name**

Panitumumab (genetical recombination)

#### **Safety measure**

Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection regarding oculomucocutaneous syndrome of the Adverse reactions section, the following text should be revised (underlined parts are revised):

Toxic epidermal necrolysis (TEN) and oculomucocutaneous syndrome (Stevens-Johnson syndrome):

Toxic epidermal necrolysis or oculomucocutaneous syndrome may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be adopted.